Rabbit Recombinant Monoclonal LAG-3 antibody. Suitable for IP, Flow Cyt (Intra), WB, IHC-P and reacts with Human samples.
pH: 7.5
Preservative: 0.05% Sodium azide
Constituents: PBS
IP | Flow Cyt (Intra) | WB | ICC/IF | IHC-P | |
---|---|---|---|---|---|
Human | Tested | Tested | Tested | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/30 | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/50 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 0.3 µg/mL | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Select an associated product type
Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:20421648, PubMed:7805750, PubMed:8647185). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:20421648, PubMed:7805750, PubMed:8647185). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185). Secreted lymphocyte activation gene 3 protein. May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
CD223, FDC, LAG3, Lymphocyte activation gene 3 protein, LAG-3
Rabbit Recombinant Monoclonal LAG-3 antibody. Suitable for IP, Flow Cyt (Intra), WB, IHC-P and reacts with Human samples.
pH: 7.5
Preservative: 0.05% Sodium azide
Constituents: PBS
Purity >99%.
LAG-3 also known as CD223 is a transmembrane protein with a mass of approximately 70 kDa. It acts as a checkpoint molecule similar to CTLA-4 and PD-1 in the immune system. LAG-3 is expressed on activated T cells natural killer cells and some dendritic cells. It interacts with its ligand MHC class II leading to inhibition of cellular proliferation and cytokine secretion an important part of immune response regulation.
LAG-3 is involved in maintaining immune homeostasis and preventing autoimmunity. It is not part of a complex but works in synergy with other immune checkpoint molecules. When interacting with MHC class II LAG-3 transmits inhibitory signals that attenuate immune cell responses. Its role in immune regulation helps to balance immune activation and tolerance which is essential for preventing tissue damage while protecting against pathogens.
The inhibitory role of LAG-3 integrates into the T cell receptor (TCR) signaling pathway and is also linked to the PD-1 signaling pathway. In TCR signaling LAG-3 negatively regulates T cell activation. LAG-3 is functionally related to proteins like PD-1 and CTLA-4 sharing similar roles in immune checkpoint pathways that are critical for maintaining immune balance.
LAG-3 has links to cancer and autoimmune diseases. In cancer LAG-3 expression on tumor-infiltrating lymphocytes correlates with immune evasion by tumors. This relationship appears in various cancers including melanoma and renal cell carcinoma. In autoimmune diseases LAG-3's expression on regulatory T cells helps control conditions such as multiple sclerosis. It collaborates with CTLA-4 in modulating immune responses that prevent excessive immune activation and tissue damage associated with autoimmunity.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
LAG-3 was immunoprecipitated from 0.35 mg HEK-293T (human embryonic kidney epithelial cell) transfected with GFP-tagged LAG-3 expression vector whole cell lysate using ab237718 at 1/30 dilution. Western blot was performed on the immunoprecipitate using ab237718 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) was used as the secondary antibody at 1/5000 dilution.
Lane 1: HEK-293T transfected with GFP-tagged LAG-3 expression vector whole cell lysate 10 μg (input).
Lane 2: ab237718 IP in HEK-293T GFP-tagged LAG-3 expression vector whole cell lysate.
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab237718 in 293T transfected with GFP-tagged LAG-3 expression vector whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 30 seconds.
This antibody also detects a 16kDa cleaved fragment. (PMID: 15557174)
All lanes: Immunoprecipitation - Anti-LAG-3 antibody [CAL25] (ab237718)
Predicted band size: 57 kDa
Observed band size: 16 kDa, 70 kDa
False colour image of Western blot: Anti-LAG-3 antibody [CAL25] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab237718 was shown to bind specifically to LAG-3. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
All lanes: Western blot - Anti-LAG-3 antibody [CAL25] (ab237718) at 1/1000 dilution
Lane 1: HDLM-2 cell lysate at 20 µg
Lane 2: Jurkat cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 57 kDa
Observed band size: 57 kDa, 70 kDa
Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling LAG-3 using ab237718 at 1/800 dilution, followed by a ready to use Goat Anti-Rabbit IgG H&L (HRP). Positive staining on the human tonsil is observed. The section was incubated with ab237718 for 15 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is a ready to use Goat Anti-Rabbit IgG H&L (HRP).
Flow cytometric analysis of 2% paraformaldehyde-fixed 0.1% Tween-20 permeabilized Human peripheral blood mononuclear cells (PBMC) treated with 10μg/ml PHA for 48h labeling LAG-3 with ab237718 at 1/50 dilution (Right) compared to a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730, Left). Goat anti rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG Fc (Alexa Fluor® 488) preadsorbed ab150097) was used as the secondary at 1/5000 dilution.
Cells were surface stained with anti-CD3 conjugated to Alexa Fluor® 647. Then fixed with 2% PFA for 10min followed by intracellular staining rabbit IgG (Left) or ab237718 (Right).
Blocking/diluting buffer and concentration: 5% NFDM/TBST
This antibody also detects a 16kDa cleaved fragment. (PMID: 15557174)
All lanes: Western blot - Anti-LAG-3 antibody [CAL25] (ab237718) at 1/1000 dilution
Lane 1: HEK-293T (human embryonic kidney epithelial cell) whole cell lysate at 20 µg
Lane 2: HEK-293T transfected with GFP-tagged LAG-3 expression vector whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 57 kDa
Observed band size: 16 kDa, 70 kDa
Exposure time: 3min
Blocking buffer and concentration: 5% NFDM/TBST
This antibody also detects a 16kDa cleaved fragment. (PMID: 15557174)
All lanes: Western blot - Anti-LAG-3 antibody [CAL25] (ab237718) at 1/1000 dilution
Lane 1: Human peripheral blood mononuclear cell (PBMC) whole cell lysate at 20 µg
Lane 2: Human peripheral blood mononuclear cell (PBMC) treated with 10μg/ml PHA for 48h whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 57 kDa
Observed band size: 16 kDa, 70 kDa
Exposure time: 3min
Formalin-fixed, paraffin-embedded human tonsil tissue stained for LAG-3 using ab237718 at 0.3 μg/ml in immunohistochemical analysis.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com